George Migausky

Massachusetts Eye & Ear Infirmary operates as hospital that provides patient care for disorders of the eye, ear, nose, throat, head and neck. It offers ophthalmology and otolaryngology research services and is a teaching partner of Harvard Medical School. The firm’s programs and services include anesthesiology, ophthalmology, otolaryngology, radiology, Coolidge Clinic laboratory and libraries. The company was founded in 1824 and is headquartered in Boston, MA.

Wellstat Management Co. LLC provides management, legal, financial, human resources, information technology, business development, transactional, investment, licensing, and other services to the Wellstat group of companies. The company was founded by Samuel J. Wohlstadter in 2007 and is headquartered in Rockville, MD.

Hyperion Catalysis International is a private company that specializes in the development and commercialization of carbon nanotubes. The company is based in Cambridge, MA. Hyperion Catalysis supplies Fibril nanotubes pre-mixed in a range of plastics for use in automotive and electronics applications. Founded in 1982, the company's flagship technology is a conductive, vapor grown, multi-walled carbon nanotube called Fibril™.

Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA.

Health Sciences Acquisitions Corp. operates as a blank check company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It pursues prospective targets that are focused on healthcare innovation domiciled in North America or Europe that are developing assets in the biopharma and medical technology sectors. The company was founded on December 06, 2018 and is headquartered in New York, NY.

Immunovant, Inc. is a biopharmaceutical company, which engages in the development of therapies for autoimmune diseases. It focuses on its product pipeline, IMVT-1401, which is a human recombinant anti-neonatal Fc receptor monoclonal antibody for the treatment of IgG mediated diseases. The company is headquartered in New York, NY.

Part of Roivant Sciences Ltd., Immunovant Sciences Ltd. develops restorative therapies for autoimmune diseases. The company is based in Hamilton, Bermuda. Immunovant Sciences was acquired by Health Sciences Acquisitions Corp. from Roivant Sciences Ltd. on December 19, 2019 for $863.06 million.